Tele: 561.316.3330
Breaking Medical Device News

Friday, October 15, 2021
HomeKlerescaKleresca® Strengthens Scientific Proof of Fluorescent Light Energy in New Study

Kleresca® Strengthens Scientific Proof of Fluorescent Light Energy in New Study

The study was peer-reviewed and published in the Journal of Clinical and Aesthetic dermatology.

In a recent, peer-reviewed study, Kleresca® presents documentation that its unique FLE technology is able to reduce inflammation in the skin, enhance collagen production, and encourage the development of new blood vessels.

The study investigated the cellular mode of action of FLE (fluorescent light energy) on skin and immune cells and combined clinical results with laboratory studies. This approach offered a unique opportunity to provide scientific answers to specific clinical questions.

The study results show how FLE reduces inflammation in the skin, enhances collagen production, and stimulates angiogenesis (the development of new blood vessels). While further research is required to fully elucidate the mode of action of FLE, the findings have important implications for Kleresca® with regards to treating inflammatory skin conditions going forward.

“These new findings are a milestone for Kleresca® as they strongly support our current range of products including FLE for acne, rosacea and skin rejuvenation and provide strong hints towards new therapeutic areas for Kleresca®“, says Kleresca® General Manager Mr. Mikkel Schoedt.

Therapeutic areas like actinic keratosis (solar keratosis), psoriasis and atopic dermatitis (eczema) are considered for the future clinical pathway for Kleresca®. As the FLE technology is painless with no serious side effects, it is considered a promising alternative to current standard treatments.

The investigative study was conducted by Kleresca® in collaboration with the University of Copenhagen, The technical University of Denmark, the University of Molise in Campobasso, Italy as well as Klox Technologies, Canada.

The study was peer-reviewed and published in the Journal of Clinical and Aesthetic dermatology.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy